Promotion of Cervical Screening among Long-term Nonattendees by Human Papillomavirus Self-sampling

다국어 초록 (Multilingual Abstract)

Cervical cancer is preventable through gynecological screening. To promote participation among non-attending women, self-collected vaginal samples for detection of high-risk human papillomavirus (hr-HPV) is an option. The aims of this study were to investigate the response of self-collected vaginal samples for hr-HPV testing among long-term non-attendees, to explore the attendance at follow-up among HPV-positive women, and to analyze the prevalence of hr-HPV and severe cervical dysplasia or cancer among the responders. A vaginal self-sampling kit was sent to 19,766 women aged 30-70 years who had not provided a cervical screening sample for ≥ 7 years in Skåne, Sweden. The self-sample was analyzed by the Aptima HPV mRNA assay (Hologic). Women testing positive for HPV were invited for follow-up. The response was 18.5% (3,646/19,757). The prevalence of HPV mRNA was 11.3% (412/3,636). Among HPV-positive women, 85.7% (353/412) attended follow-up, and of these, 44.8% (158/353) had HPV in the cervical sample. The HPV mRNA test of self-samples showed a positive predictive value of 9.3% ([33/353], 95% CI = 6.5-12.9) for detection of cytologically severe dysplasia. Histologically severe dysplasia or cancer was detected in 0.88% ([32/3,636], 95% CI = 0.6-1.2) among responders, including two cervical- and one vaginal cancer. In conclusion, almost one fifth of the long-term non-attendees participated in self-collected vaginal hr-HPV sampling. The prevalence of histologically confirmed high grade squamous intraepithelial lesion or cervical cancer was not increased significantly compared to regularly screened women in Sweden. The relatively high HPV prevalence among the self-samples indicates the importance of diagnostic follow-up with cervical HPV testing and reflex-cytology of HPV-positive cases.
Key Words Uterine cervical neoplasms, Scr

참고문헌 (Reference)

1 Nelson EJ, "The acceptability of self-sampled screening for HPV DNA : a systematic review and meta-analysis" 93 : 56-61, 2017

2 "The Swedish National Quality Register of Gynecological Surgery (Gynop)"

3 Austin RM, "Technology matters: the clinical utility of HPV mRNA testing compared to DNA testing"

4 Regional Cancer Centers (RCC), "Status of the introduction of the cervical cancer prevention program"

5 National Board of Health and Welfare, "Statistical database for cancer"

6 Gyllensten U, "Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer" 105 : 694-697, 2011

7 Sanner K, "Selfsampling of the vaginal fluid at home combined with high-risk HPV testing" 101 : 871-874, 2009

8 Asciutto KC, "Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples" 101 : 69-73, 2018

9 Enerly E, "Self-sampling for human papillomavirus testing among nonattenders increases attendance to the Norwegian Cervical Cancer Screening Programme" 11 : e0151978-, 2016

10 Virtanen A, "Self-sampling experiences among non-attendees to cervical screening" 135 : 487-494, 2014

11 Andrae B, "Screening-preventable cervical cancer risks : evidence from a nationwide audit in Sweden" 100 : 622-629, 2008

12 Gustavsson I, "Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology" 118 : 896-904, 2018

13 Tranberg M, "Preventing cervical cancer using HPV selfsampling : direct mailing of test-kits increases screening participation more than timely opt-in procedures-a randomized controlled trial" 18 : 273-, 2018

14 Lindroth Y, "Population-based primary HPV mRNA cervical screening compared with cytology screening" 124 : 61-66, 2019

15 Swedish National Cervical Screening Registry, "Ouality indicatorscrossreference cytology- histopathology organized screening"

16 Broberg G, "Increasing participation in cervical cancer screening : offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial" 134 : 2223-2230, 2014

17 Des Marais AC, "Home self-collection by mail to test for human papillomavirus and sexually transmitted infections" 132 : 1412-1420, 2018

18 Bulkmans NW, "High-risk HPV type-specific clearance rates in cervical screening" 96 : 1419-1424, 2007

19 Stenvall H, "High prevalence of oncogenic human papilloma virus in women not attending organized cytological screening" 87 : 243-245, 2007

20 Gök M, "HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study" 340 : c1040-, 2010

21 Szarewski A, "HPV self-sampling as an alternative strategy in non-attenders for cervical screening-a randomised controlled trial" 104 : 915-920, 2011

22 Chernesky M, "Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7messenger RNA in cervical and vaginal samples" 41 : 365-368, 2014

23 Ernstson A, "Detection of HPV mRNA in self-collected vaginal samples among women at 69-70 years of age" 39 : 381-386, 2019

24 Darlin L, "Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening" 58 : 155-160, 2013

25 Arbyn M, "Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses" 363 : k4823-, 2018

26 Regional Cancer Centers (RCC), "Cervical cancer prevention- National care program"

27 Ernstson A, "Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection" 15 : 10-, 2020

28 Regional Cancer Centers (RCC), "Cervical cancer and vaginal cancer- National care program"

29 Wikström I, "Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening" 86 : 720-725, 2007

30 Liselotte Coorevits, "Are vaginal swabs comparable to cervical smears for human papillomavirus DNA testing?" 대한부인종양학회 29 (29): 1-11, 2018

31 Castle PE, "A comparison of cervical and vaginal human papillomavirus" 34 : 849-855, 2007